FLT3LG and melanoma: In in a phase II study (NCT02129075, Table 2), CDX‐1401 was administered to patients with resected melanoma following pretreatment with CDX‐301, a recombinant human Flt3 ligand (Flt3L), which is known to expand circulating DCs, and poly‐ICLC (a TLR3 agonist).